JP Morgan analyst William Cuddy downgrades Blucora (NASDAQ:BCOR) from Overweight to Neutral and lowers the price target from $27 to $22.
Analyst Ratings for Regeneron Pharmaceuticals
Within the last quarter, Regeneron Pharmaceuticals (NASDAQ:REGN) has observed the following analyst ratings: